2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

NCT02624700 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Breast Cancer
Recurrent Breast Cancer

Interventions

DRUG: Experimental Arm A: Pemetrexed
DRUG: Experimental Arm A: Sorafenib
DRUG: Experimental Arm B: Pemetrexed
DRUG: Experimental Arm B: Sorafenib

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]
[object Object]